Globus Medical downgraded to Underperform, premium valuation, says BofA/Merrill. As previously reported, BofA/Merrill downgraded Globus Medical (GMED) to Underperform from Neutral and lowered its price target to $55. Analyst Bob Hopkins said shares are trading at a premium to peers in faster growth markets and notes speculation in the market that Medtronics (MDT) could launch a very competitive spine robot with navigation in January 2019
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.